Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Gustavo H Vazquez

Showing results (1-10 of 21) with videos related to

Pageof 3
Sort By:
Journal of Affective Disorders|September 7, 2022
Association between peripheral biomarkers and clinical response to IV ketamine for unipolar treatment-resistant depression: An open label studyMelody J Y Kang, Gustavo H Vazquez
The Psychiatric Clinics of North America|February 4, 2020
Suicidal Behavior Associated with Mixed Features in Major Mood DisordersLeonardo Tondo, Gustavo H Vazquez, Ross J Baldessarini
Journal of Affective Disorders|January 8, 2021
Response to commentary on the comparative efficacy of esketamine vs. ketamine meta-analysis: Putting the cart before the horse?Anees Bahji, Gustavo H Vazquez, Carlos A Zarate
Journal of Affective Disorders|October 6, 2020
Comparative efficacy of racemic ketamine and esketamine for depression: A systematic review and meta-analysisAnees Bahji, Gustavo H Vazquez, Carlos A Zarate
Journal of Affective Disorders|November 24, 2020
Erratum to "Comparative efficacy of racemic ketamine and esketamine for depression: a systematic review and meta-analysis" [Journal of Affective Disorders 278C (2021) 542-555]Anees Bahji, Gustavo H Vazquez, Carlos A Zarate
Frontiers in Psychiatry|March 18, 2024
Editorial: Old treatments new outcomes-augmentation treatments for depressionNicolas A Nuñez, Boney Joseph, Gustavo H Vazquez
Expert Opinion on Drug Safety|March 1, 2022
Efficacy and safety of racemic ketamine and esketamine for depression: a systematic review and meta-analysisAnees Bahji, Carlos A Zarate, Gustavo H Vazquez
Journal of Affective Disorders|December 27, 2022
Response to "Letter to the Editor: Comparative efficacy of racemic ketamine and esketamine for depression: A systematic review and meta-analysis."Anees Bahji, Gustavo H Vazquez, Carlos A Zarate
The International Journal of Neuropsychopharmacology|April 30, 2021
Ketamine for Bipolar Depression: A Systematic ReviewAnees Bahji, Carlos A Zarate, Gustavo H Vazquez
CNS & Neurological Disorders Drug Targets|August 1, 2017
Potential Novel Treatments for Bipolar Depression: Ketamine, Fatty Acids, Anti-inflammatory Agents, and ProbioticsGustavo H Vazquez, Sebastian Camino, Leonardo Tondo, et al.
Pageof 3

Showing results (1-10 of 21) with videos related to

Sort By:
Pageof 3
Journal of Affective Disorders|September 7, 2022
Association between peripheral biomarkers and clinical response to IV ketamine for unipolar treatment-resistant depression: An open label studyMelody J Y Kang, Gustavo H Vazquez
The Psychiatric Clinics of North America|February 4, 2020
Suicidal Behavior Associated with Mixed Features in Major Mood DisordersLeonardo Tondo, Gustavo H Vazquez, Ross J Baldessarini
Journal of Affective Disorders|January 8, 2021
Response to commentary on the comparative efficacy of esketamine vs. ketamine meta-analysis: Putting the cart before the horse?Anees Bahji, Gustavo H Vazquez, Carlos A Zarate
Journal of Affective Disorders|October 6, 2020
Comparative efficacy of racemic ketamine and esketamine for depression: A systematic review and meta-analysisAnees Bahji, Gustavo H Vazquez, Carlos A Zarate
Journal of Affective Disorders|November 24, 2020
Erratum to "Comparative efficacy of racemic ketamine and esketamine for depression: a systematic review and meta-analysis" [Journal of Affective Disorders 278C (2021) 542-555]Anees Bahji, Gustavo H Vazquez, Carlos A Zarate
Frontiers in Psychiatry|March 18, 2024
Editorial: Old treatments new outcomes-augmentation treatments for depressionNicolas A Nuñez, Boney Joseph, Gustavo H Vazquez
Expert Opinion on Drug Safety|March 1, 2022
Efficacy and safety of racemic ketamine and esketamine for depression: a systematic review and meta-analysisAnees Bahji, Carlos A Zarate, Gustavo H Vazquez
Journal of Affective Disorders|December 27, 2022
Response to "Letter to the Editor: Comparative efficacy of racemic ketamine and esketamine for depression: A systematic review and meta-analysis."Anees Bahji, Gustavo H Vazquez, Carlos A Zarate
The International Journal of Neuropsychopharmacology|April 30, 2021
Ketamine for Bipolar Depression: A Systematic ReviewAnees Bahji, Carlos A Zarate, Gustavo H Vazquez
CNS & Neurological Disorders Drug Targets|August 1, 2017
Potential Novel Treatments for Bipolar Depression: Ketamine, Fatty Acids, Anti-inflammatory Agents, and ProbioticsGustavo H Vazquez, Sebastian Camino, Leonardo Tondo, et al.
Pageof 3